Literature DB >> 27144920

Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic 131I in the differentiated thyroid cancers.

Paula Grasiele Carvalho Trevizam1, José Vicente Tagliarini2, Emanuel Celice Castilho2, Mariângela de Alencar Marques3, Yoshio Kiy4, Gláucia Maria Ferreira da Silva Mazeto1.   

Abstract

BACKGROUND: Stimulated thyroglobulin (STg) levels in patients with differentiated thyroid carcinomas (DTCs) after total thyroidectomy (TT) and before radioactive iodine (131I) ablation/therapy (RIT) are predictive of therapeutic success but can be influenced by the thyroid-stimulating hormone (TSH) level.
OBJECTIVES: This study compared the reliability of the STg/TSH ratio and STg measurement in predicting the success of RIT.
METHODS: Sixty-three DTC patients submitted to TT were assessed retrospectively to compare the ability of STg level and the STg/TSH ratio to predict successful RIT.
RESULTS: In this study 48 (76.2%) patients had successful RIT. The successful and unsuccessful groups received different 131I doses and had different STg levels and STg/TSH ratios. The STg and STg/TSH ratio cutoff values that predicted successful RIT were 4.41 ng/mL (sensitivity of 86.7% and specificity of 77%) and 0.093 (sensitivity of 80% and specificity of 79.2%), respectively. Age, STg level, STg/TSH ratio, and 131I dose were associated with successful RIT, but after multivariate analysis only STg remained associated (p < 0.05).
CONCLUSION: In conclusion, our data suggest that the STg/TSH ratio and measurement of STg are equally reliable in predicting successful RIT in DTC patients.

Entities:  

Keywords:  Biological markers; prognosis; thyroglobulin; thyroid neoplasms; thyrotropin

Mesh:

Substances:

Year:  2016        PMID: 27144920     DOI: 10.3109/07435800.2016.1173056

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  7 in total

1.  A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis.

Authors:  Zhong Ying Rui; Yang Liu; Wei Zheng; Xuan Wang; Zhao Wei Meng; Jian Tan; Ning Li; Qiang Jia
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

2.  Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer.

Authors:  Yansong Lin; Chen Wang; Wen Gao; Ruixue Cui; Jun Liang
Journal:  Oncotarget       Date:  2017-06-27

3.  The Prognostic Role of Postablative Non-Stimulated Thyroglobulin in Differentiated Thyroid Cancer.

Authors:  Szabina Szujo; Laszlo Bajnok; Beata Bodis; Zsuzsanna Nagy; Orsolya Nemes; Karoly Rucz; Emese Mezosi
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

4.  The diagnostic and predictive accuracy of thyroglobulin to TSH ratio and TSH to thyroglobulin ratio in detecting differentiated thyroid carcinoma in normothyroid patients with thyroid nodules: A retrospective cohort study and systematic review of the literature.

Authors:  Evangelos Karvounis; Ioannis Kappas; Anna Angelousi; George-Marios Makris; Thomas D Siamatras; Eva Kassi
Journal:  Oncol Rev       Date:  2021-01-11

5.  Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of 131I Therapy in Patients With Differentiated Thyroid Cancer Following Total Thyroidectomy: A Retrospective Study.

Authors:  Mengjiao Pan; Zhuyao Li; Meng Jia; Xiubo Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-06       Impact factor: 6.055

Review 6.  The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer.

Authors:  Sha Li; Chutong Ren; Yi Gong; Fei Ye; Yulong Tang; Jiangyue Xu; Can Guo; Jiangsheng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

7.  The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas.

Authors:  Isabela de Oliveira Amui; José Vicente Tagliarini; Emanuel C Castilho; Mariângela de Alencar Marques; Yoshio Kiy; José Eduardo Corrente; Gláucia M F S Mazeto
Journal:  Braz J Otorhinolaryngol       Date:  2017-10-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.